| Titre |
A Prospective, Multi-center Investigational Study of IMMray™ PanCan-d Diagnostic Assay for Early Detection of Pancreatic Ductal Adenocarcinoma in High-risk Populations |
| Protocole ID |
PanFAM-1 |
| ClinicalTrials.gov ID |
NCT03693378 |
| Type(s) de cancer |
Pancréas |
| Phase |
Autres |
| Type étude |
Diagnostic |
| Institution |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 SITE GLEN
1001 boul. Décarie , Montréal, QC, H4A 3J1
|
| Ville |
Montréal |
| Investigateur(trice) principal(e) |
Dr George Zogopoulos
|
| Coordonnateur(trice) |
Adeline Cuggia
514-934-1934 poste 76333
|
| Statut |
![]() Fermé |
| Critètes d'éligibilité |
- Ability to understand and the willingness to sign a written informed consent document
- Individuals with the following family phenotype and age:
- Two or more relatives with pancreatic adenocarcinomas (PDAC) on the same side of the family, where two PDAC-affected individuals are first degree related (FDR) + at least one PDAC-affected individual is a FDR of the Participant (≥50 years old OR 10 years before onset in family)
- Two affected FDR with PDAC (≥50 years old OR 10 years before onset of an FDR)
- Any of BRCA1, BRCA2, PALB2, ATM mutations confirmed pathogenic or likely pathogenic + one FDR or secondary degree related (SDR) with PDAC (≥50 years old OR 10 years before onset of an FDR and SDR)
- Familial atypical multiple mole-melanoma (FAMMM) with confirmed pathogenic or likely pathogenic mutation variants in: p16, CDKN2A (≥50 years old)
- Known mutation carrier for STK11 (Peutz Jeghers Syndrome) (≥35 years old)
- Lynch syndrome (HNPCC) with confirmed pathogenic or likely pathogenic variants in: MLH1, MSH2, MSH6, PMS2, or EPCAM + one FDR or SDR with PDAC (≥50 years old OR 10 years before onset of an FDR or SDR)
- Hereditary pancreatitis with confirmed PRSS1 pathogenic or likely pathogenic history of pancreatitis (≥40 years old)
|
| Critètes d'exclusion |
|
Groupe d'étude en oncologie du Québec